JP2024523525A5 - - Google Patents

Info

Publication number
JP2024523525A5
JP2024523525A5 JP2023579274A JP2023579274A JP2024523525A5 JP 2024523525 A5 JP2024523525 A5 JP 2024523525A5 JP 2023579274 A JP2023579274 A JP 2023579274A JP 2023579274 A JP2023579274 A JP 2023579274A JP 2024523525 A5 JP2024523525 A5 JP 2024523525A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
stereoisomer
acceptable salt
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/100685 external-priority patent/WO2022268152A1/zh
Publication of JP2024523525A publication Critical patent/JP2024523525A/ja
Publication of JP2024523525A5 publication Critical patent/JP2024523525A5/ja
Pending legal-status Critical Current

Links

JP2023579274A 2021-06-24 2022-06-23 Glp-1受容体アゴニストならびにその組成物および使用 Pending JP2024523525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110702643 2021-06-24
CN202110702643.0 2021-06-24
PCT/CN2022/100685 WO2022268152A1 (zh) 2021-06-24 2022-06-23 Glp-1受体激动剂及其组合物和用途

Publications (2)

Publication Number Publication Date
JP2024523525A JP2024523525A (ja) 2024-06-28
JP2024523525A5 true JP2024523525A5 (cg-RX-API-DMAC7.html) 2025-06-27

Family

ID=84544137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579274A Pending JP2024523525A (ja) 2021-06-24 2022-06-23 Glp-1受容体アゴニストならびにその組成物および使用

Country Status (18)

Country Link
US (2) US11981666B2 (cg-RX-API-DMAC7.html)
EP (1) EP4361145A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523525A (cg-RX-API-DMAC7.html)
KR (1) KR20240024910A (cg-RX-API-DMAC7.html)
CN (2) CN117098758A (cg-RX-API-DMAC7.html)
AU (1) AU2022300055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219984A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003794A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017726A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230611A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000275A (cg-RX-API-DMAC7.html)
EC (1) ECSP23095307A (cg-RX-API-DMAC7.html)
IL (1) IL309235A (cg-RX-API-DMAC7.html)
MX (1) MX2023014985A (cg-RX-API-DMAC7.html)
PE (1) PE20241794A1 (cg-RX-API-DMAC7.html)
TW (1) TW202317553A (cg-RX-API-DMAC7.html)
WO (1) WO2022268152A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202400786B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
LT4271672T (lt) 2021-04-21 2026-03-10 Gilead Sciences, Inc. Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
KR20240053617A (ko) 2021-08-30 2024-04-24 민드랭크 에이아이 리미티드 Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
AU2023394509A1 (en) * 2022-12-13 2025-07-10 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof
JP2026501161A (ja) * 2022-12-13 2026-01-14 杭州中美華東製薬有限公司 Glp-1受容体作動薬の新規結晶形、その製造方法、その医薬組成物およびその使用
CN118496200A (zh) * 2023-02-14 2024-08-16 成都康弘药业集团股份有限公司 吲唑啉酮类化合物及其制备方法和用途
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN121866253A (zh) 2023-07-04 2026-04-14 杭州中美华东制药有限公司 一种glp1r激动剂及其中间体的制备方法
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
TW202612693A (zh) * 2024-06-05 2026-04-01 大陸商杭州中美華東製藥有限公司 Glp-1受體激動劑的口服藥物組合物及其製備方法
WO2026049510A1 (en) * 2024-08-28 2026-03-05 Yuhan Corporation Thienoimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof
TW202615019A (zh) * 2024-09-05 2026-04-16 大陸商杭州中美華東製藥有限公司 Glp-1r激動劑與恩格列淨的藥物組合物及用途
CN119837849B (zh) * 2025-02-10 2025-06-13 中国科学院北京基因组研究所(国家生物信息中心) 蜡菊素在制备缓解和治疗受试者细胞红系分化障碍的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
US10723699B2 (en) 2015-11-04 2020-07-28 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2018109607A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
KR101910586B1 (ko) 2017-03-03 2018-10-23 한국화학연구원 헤테로아릴이 치환된 2-페닐이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 GLP-1 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
WO2021018023A1 (zh) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CR20220178A (es) * 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
CN115697999A (zh) * 2020-02-13 2023-02-03 加舒布鲁姆生物公司 杂环glp-1激动剂
CN115515956B (zh) * 2020-09-29 2024-06-25 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
EP4247804A1 (en) * 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4271674B9 (en) * 2021-04-21 2026-03-11 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds

Similar Documents

Publication Publication Date Title
RU2470011C2 (ru) Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
JP2024529527A5 (cg-RX-API-DMAC7.html)
JP2012509903A5 (cg-RX-API-DMAC7.html)
CA2566945A1 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
JP2010529203A5 (cg-RX-API-DMAC7.html)
JP2022081661A5 (cg-RX-API-DMAC7.html)
AU2013309124B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
RU2011105422A (ru) Дейтерированные бензилбензольные производные и способы применения
JP2018517746A5 (cg-RX-API-DMAC7.html)
IL309235A (en) GLP-1 receptor agonist and its preparation and use
JP2011528370A5 (cg-RX-API-DMAC7.html)
JP2022510925A5 (cg-RX-API-DMAC7.html)
JP2015518491A5 (cg-RX-API-DMAC7.html)
CA2594684A1 (en) Morpholines as 5ht2c agonists
JP2020528938A5 (cg-RX-API-DMAC7.html)
RU2016104890A (ru) Производные 1,7-нафтиридина
JP2022529061A5 (cg-RX-API-DMAC7.html)
JP2010504321A5 (cg-RX-API-DMAC7.html)
JP2023525359A5 (cg-RX-API-DMAC7.html)
RU2015148927A (ru) Производные изохинолина, стимулирующие нейрогенез
RU2006138494A (ru) 1, 3, 4-оксадиазол-2-оны в качестве модуляторов ppar-ельта и их применение
RU2007144076A (ru) Новое производное лактама
RU2013127611A (ru) Модуляторы глюкагонового рецептора
JP2024510249A5 (cg-RX-API-DMAC7.html)
JP2023531411A5 (cg-RX-API-DMAC7.html)